Moderna Names Horning to Board of Directors
5 February 2020 - - Sandra Horning, M.D., FACP, FASCO, has been nominated to join US-based biotechnology company Moderna, Inc.'s (NASDAQ: MRNA) board of directors effective as of April 29, 2020, the date of the company's annual meeting of stockholders, the company said.

Horning has been nominated as a Class II director and will serve as a member of the Product Development Committee of the board.

Horning is an academic and industry veteran, most recently serving as chief medical officer and head of global product development at Genentech/Roche (SIX: RO) (OTCQX: RHHBY).

Horning is currently a co-founder and advisor for EQRx, a biotechnology company focused on creating innovative medicines at lower prices, and serves on the board of directors of Gilead Sciences, Inc. (NASDAQ: GILD).

Previously she served as chief medical officer and head of global product development at Genentech/Roche from 2014 to 2019.

Over the course of a decade, she oversaw the approval of 15 new medicines across a variety of diseases, including cancer, multiple sclerosis, influenza and blindness.

Prior to joining Genentech, she spent more than 20 years as a Professor of Medicine, Oncology and Blood and Bone Marrow Transplantation at Stanford University School of Medicine, where she remains an Emerita Professor.

She has received numerous awards and recognitions throughout her career she is the recipient of the Healthcare Businesswomen's Association 2020 Woman of the Year, 2017 Duane Roth Memorial Award, 2014 Fierce Biotech Top Women in Biotech Award and 2010 Top Women in Bay Area Business Award.

She was president of the American Society of Clinical Oncology from 2005-2006 and has served on the editorial boards of several peer-reviewed medical journals, including Journal of Clinical Oncology, Clinical Cancer Research, Clinical Lymphoma, Leukemia and Lymphoma, the Annals of Internal Medicine and the American Journal of Medicine.

Horning received her M.D. from University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University.

Moderna is advancing messenger RNA science to create a new class of transformative medicines for patients.

mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases.

Moderna's platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the company the capability to pursue in parallel a robust pipeline of new development candidates.

Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. (NASDAQ: AZN) and Merck, Inc. (NASDAQ: MRK), as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the US Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant secretary for Preparedness and Response within the US Department of Health and Human Services.

Moderna has been named a top biopharmaceutical employer by Science for the past five years.